Hormone

Testosterone / TRT

Well-established hormone replacement with decades of clinical data.

Androgen receptor signalingIGF-1/mTORMyostatin/FollistatinAromatase (CYP19A1)

88 A

Evidence Score

ⓘ For informational purposes only — not medical advice.

Score Breakdown

Overview

Testosterone replacement therapy (TRT) is one of the most well-characterized hormone therapies in medicine, with decades of clinical use for hypogonadism. FDA-approved formulations span injectable, transdermal, and oral routes. The TRAVERSE cardiovascular safety trial (2023) provided long-awaited safety data.

Mechanism of Action

Testosterone binds the androgen receptor (AR), translocating to the nucleus to modulate gene expression across muscle, bone, fat, brain, and reproductive tissues. AR-mediated transcription upregulates genes involved in protein synthesis (myofibrillar proteins), suppresses myostatin, and modulates IGF-1 signaling.

Evidence Base

FDA-approved for male hypogonadism with extensive RCT data including the TRAVERSE trial (n=5,246). Endocrine Society clinical practice guidelines provide evidence-based dosing and monitoring recommendations. Published literature spans thousands of studies over 80+ years.

Gene Pathway Detail

Androgen receptor activation drives transcription of muscle-specific genes (MYH1, MYH2), suppresses myostatin (MSTN) expression, upregulates follistatin (FST), and modulates aromatase (CYP19A1) for estrogen conversion. Biomeme can monitor AR-responsive gene panels to confirm TRT is achieving target tissue engagement.

mRNA Monitoring Insight

TRT produces measurable mRNA changes in androgen-responsive genes within 2–4 weeks. Monitoring AR-mediated transcription provides molecular confirmation that testosterone is reaching target tissues at therapeutic levels — complementing serum testosterone measurements with functional pathway data.

Safety Considerations

FDA-approved with well-defined safety profile. Monitoring requirements include hematocrit (polycythemia risk), PSA, lipids, and liver function. The TRAVERSE trial showed no increased cardiovascular risk. Contraindicated in prostate/breast cancer, polycythemia, and severe sleep apnea.

FAQ

Is TRT safe long-term?

The TRAVERSE trial (2023) demonstrated non-inferiority for cardiovascular safety versus placebo in men with hypogonadism and cardiovascular risk factors. Long-term safety requires ongoing monitoring of hematocrit, PSA, and metabolic parameters.

Quick Facts

Category: Hormone
Score: 88/100 (A)
Gene Pathways: 4 characterized

Sources

[1] TRAVERSE Trial — NEJM 2023

Compare Others

Monitor Your Peptide Response.

Biomeme's transcriptomic platform tracks molecular pathway engagement so you know if your therapy is working.